orforglipron vs Semaglutide (Ozempic)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
orforglipron · Foundayo
Marketed by Eli Lilly and partners
NCT05803421 · Phase 3 · completed
ACHIEVE-4 was a randomized, open-label, event-driven Phase 3 trial. It assigned 2,749 adults with type 2 diabetes, obesity or overweight and established cardiovascular or chronic kidney disease to oral orforglipron or injected insulin glargine once daily. The primary endpoint was time to the first major cardiovascular event, and orforglipron had to be shown non-inferior to insulin glargine, with the upper limit of the 95% confidence interval for the hazard ratio below 1.8. Over a median of 2 years, events occurred in 4.2% of orforglipron patients and 5.0% of insulin glargine patients (hazard ratio 0.84, 95% CI 0.59 to 1.20), so non-inferiority was shown and the trial met its primary endpoint. The figures come from the peer-reviewed paper in The Lancet.
Next expected readout: May 2027 · NCT07613307 (registry estimate)
Reported efficacy
Mean Percent Change from Baseline in Body Weight (Baseline, Week 72): Body weight change from baseline to Week 72 (treatment-regimen estimand): -9.6% orforglipron 17.2 mg vs -2.5% placebo (p<.001 for all orforglipron doses vs placebo); HbA1c change: -1.66% (17.2 mg) vs -0.47% placebo (p<.001) (met)
Result source: NCT05872620
Semaglutide (Ozempic)
Marketed by Novo Nordisk
NCT01720446 · Phase 3 · completed
This was a large randomized, double-blind, placebo-controlled trial with 1,648 participants receiving semaglutide and 1,649 receiving placebo. The hard clinical primary endpoint, first major adverse cardiovascular event, occurred in 6.6% versus 8.9% of participants; the prespecified non-inferiority comparison was met (hazard ratio 0.74, 95% CI 0.58–0.95, p<0.0001), and a post hoc superiority analysis was statistically significant (p=0.0167).
Next expected readout: November 2026 · NCT06954090 (registry estimate)
Reported efficacy
Number of Participants From Time of Randomization to First Occurrence of Onset of Persistent ≥50% Reduction in eGFR(CKD-EPI); Onset of Persistent eGFR(CKD-EPI) <15mL/Min/1.73m^2; Initiation of Chronic Renal Replacement Therapy; Renal Death; CV Death (From Week 0 up to Week 234): Primary composite kidney outcome (kidney failure, sustained >=50% eGFR decline, or death from kidney/cardiovascular causes): 331 first events (semaglutide) vs 410 first events (placebo); HR 0.76 (95% CI 0.66-0.88), P=0.0003. (met)
Result source: NCT03819153
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | orforglipron | Semaglutide (Ozempic) |
|---|---|---|
| HbA1c, change | -1.4% vs -0.1%−1.3 vs placeboNCT0597194014 other results
| -1.6% vs 0%−1.6 vs placeboNCT0205489735 other results
|
| Body weight, change (kg) | -7.3 vs -1.3−6 vs placeboNCT059719407 other results
| -4.9 vs -0.6−4.3 vs placeboNCT0172044632 other results
|
| HbA1c below 7% | 79.0% vs 37.1%+41.9 vs placeboNCT059719407 other results
| 72.3% vs 24.8%+47.5 vs placeboNCT0205489710 other results
|
| Fasting plasma glucose, change | -2.0 vs -1.1−0.9 vs placeboNCT044264744 other results
| -2.1 vs -0.9−1.2 vs placeboNCT0172044624 other results
|
| 3-point MACE (% with event) | —Not posted · NCT05803421 | 6.6% vs 8.9%−2.3 vs placeboNCT017204461 other result
|
HbA1c, change
- orforglipron
- -1.4% vs -0.1%−1.3 vs placeboNCT05971940
14 other results
- -1.6% vs -0.1% NCT05971940
- -1.3% vs -0.1% NCT05971940
- -2.0% vs -0.4% NCT05048719
- -1.9% vs -0.4% NCT05048719
- -1.2% vs -0.4% NCT05048719
- -2.1% vs -0.4% NCT05048719
- -1.8% vs -0.4% NCT05048719
- -2.0% vs -1.1% NCT05048719
- -1.9% vs -1.1% NCT05048719
- -1.2% vs -1.1% NCT05048719
- -2.1% vs -1.1% NCT05048719
- -1.8% vs -1.1% NCT05048719
- -1.7% vs -0.5% NCT05872620
- 1.7% vs 0.8% NCT06192108
- Semaglutide (Ozempic)
- -1.6% vs 0%−1.6 vs placeboNCT02054897
35 other results
- -1.9% vs -0.1% NCT02305381
- -1.6% vs -0.2% NCT03086330
- -1.5% vs 0% NCT02054897
- -1.4% vs -0.1% NCT02305381
- -1.5% vs -0.9% NCT01885208
- -1.6% vs -0.6% NCT01930188
- -1.8% vs -1.1% NCT02648204
- -1.6% vs -0.8% NCT02128932
- -1.7% vs -1.1% NCT03191396
- -1.3% vs -0.6% NCT01930188
- -1.5% vs -1.1% NCT02648204
- -1.2% vs -0.8% NCT02128932
- -1.5% vs -1.2% NCT03689374
- -1.4% vs -0.7% NCT05514535
- -1.4% vs -0.4% NCT01720446
- -1.1% vs -0.4% NCT01720446
- -0.9% vs -0.0% NCT03819153
- -1.8% vs -0.3% NCT05649137
- -0.8% vs 0.2% NCT04560998
- -2.0% vs -0.7% NCT02207374
- -2.2% vs -0.7% NCT02254291
- -1.7% vs -0.7% NCT02207374
- -1.9% vs -0.7% NCT02254291
- -1.4% vs -0.7% NCT05514535
- -1.9% vs -1.1% NCT05486065
- -1.1% vs -0.4% NCT05144984
- -2.1% vs -1.1% NCT05486065
- -1.8% vs -1.1% NCT05486065
- -2.3% vs -0.4% NCT05144984
- -2.2% vs -0.4% NCT05144984
- -2.2% vs -0.4% NCT05144984
- -2.3% vs -0.4% NCT05144984
- -0.5% vs 0% NCT04538352
- -1.5% vs -1.1% NCT03596450
- -1.4% vs -1.0% NCT03596450
Body weight, change (kg)
- orforglipron
- -7.3 vs -1.3−6 vs placeboNCT05971940
7 other results
- -5.5 vs -1.3 NCT05971940
- -4.4 vs -1.3 NCT05971940
- -9.5 vs -2.2 NCT05048719
- -6.5 vs -2.2 NCT05048719
- -3.7 vs -2.2 NCT05048719
- -10.1 vs -2.2 NCT05048719
- -9.7 vs -2.2 NCT05048719
- Semaglutide (Ozempic)
- -4.9 vs -0.6−4.3 vs placeboNCT01720446
32 other results
- -3.6 vs -0.6 NCT01720446
- -5.5 vs -1.4 NCT03819153
- -4.7 vs -0.9 NCT02054897
- -6.4 vs -1.4 NCT02305381
- -4.7 vs -1 NCT03086330
- -3.7 vs -0.9 NCT02054897
- -3.7 vs -1.4 NCT02305381
- -14.9 vs -4.6 NCT05649137
- -5.2 vs -1.2 NCT04560998
- -6.5 vs -2.3 NCT02648204
- -5.2 vs 1.1 NCT02128932
- -4.2 vs -0.4 NCT03061214
- -5.8 vs -2 NCT03191396
- -5.6 vs -1.9 NCT01885208
- -6.1 vs -1.9 NCT01930188
- -4.6 vs -2.3 NCT02648204
- -3.5 vs 1.1 NCT02128932
- -3 vs -0.4 NCT03061214
- -4.3 vs -1.9 NCT01930188
- -8.0 vs 0.4 NCT05514535
- -4.2 vs 2.9 NCT03689374
- -5.7 vs -4.3 NCT03136484
- -8.9 vs -2.3 NCT05486065
- -4.7 vs -2.6 NCT05144984
- -13.1 vs -2.3 NCT05486065
- -10.1 vs -2.3 NCT05486065
- -8.9 vs -2.6 NCT05144984
- -12 vs -2.6 NCT05144984
- -10 vs -2.6 NCT05144984
- -12 vs -2.6 NCT05144984
- -5 vs -3.1 NCT03596450
- -8.6 vs 1.4 NCT04538352
HbA1c below 7%
- orforglipron
- 79.0% vs 37.1%+41.9 vs placeboNCT05971940
7 other results
- 81.3% vs 37.1% NCT05971940
- 78.2% vs 37.1% NCT05971940
- 92.8% vs 24.3% NCT05048719
- 78.9% vs 24.3% NCT05048719
- 65.2% vs 24.3% NCT05048719
- 95.8% vs 24.3% NCT05048719
- 91.2% vs 24.3% NCT05048719
- Semaglutide (Ozempic)
- 72.3% vs 24.8%+47.5 vs placeboNCT02054897
10 other results
- 78.6% vs 10.5% NCT02305381
- 82.5% vs 20.5% NCT03086330
- 74.2% vs 24.8% NCT02054897
- 60.6% vs 10.5% NCT02305381
- 78.7% vs 52.2% NCT02648204
- 84% vs 49.6% NCT03061214
- 80.4% vs 45.9% NCT03191396
- 68.4% vs 52.2% NCT02648204
- 74.5% vs 49.6% NCT03061214
- 76.1% vs 50.8% NCT03136484
Fasting plasma glucose, change
- orforglipron
- -2.0 vs -1.1−0.9 vs placeboNCT04426474
4 other results
- -3 vs -1.1 NCT04426474
- -2.9 vs -1.1 NCT04426474
- -2.4 vs -1.1 NCT04426474
- -2.3 vs -1.1 NCT04426474
- Semaglutide (Ozempic)
- -2.1 vs -0.9−1.2 vs placeboNCT01720446
24 other results
- -1.8 vs -0.9 NCT01720446
- -2.4 vs -0.6 NCT02054897
- -2.4 vs -0.5 NCT02305381
- -2.3 vs 0.1 NCT03086330
- -2.4 vs -0.6 NCT02054897
- -1.6 vs -0.5 NCT02305381
- -3.3 vs -1.1 NCT05649137
- -2.8 vs -2 NCT01885208
- -2.6 vs -1.1 NCT01930188
- -2.8 vs -1.9 NCT02648204
- -2.7 vs -2.1 NCT02128932
- -2.6 vs -1 NCT03061214
- -2.6 vs -1.5 NCT03191396
- -2.1 vs -1.1 NCT01930188
- -2.2 vs -1.9 NCT02648204
- -2.0 vs -2.1 NCT02128932
- -1.3 vs -0.8 NCT03689374
- -2.2 vs -1 NCT03061214
- -2.5 vs -2 NCT03136484
- -1.4 vs -0.1 NCT05144984
- -3.9 vs -0.1 NCT05144984
- -3.4 vs -0.1 NCT05144984
- -3.8 vs -0.1 NCT05144984
- -3.8 vs -0.1 NCT05144984
3-point MACE (% with event)
- orforglipron
- —Not posted · NCT05803421
- Semaglutide (Ozempic)
- 6.6% vs 8.9%−2.3 vs placeboNCT01720446
1 other result
- 12% vs 14.4% NCT03819153
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
12 other shared endpoints and safety
Coverage. orforglipron: 16 of 16 rows · Semaglutide (Ozempic): 16 of 16 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | orforglipron Rows use multiple source trials | Semaglutide (Ozempic) Rows use multiple source trials |
|---|---|---|
| BMI absolute change · kg No placebo or comparator arm | -2.5 kg @ 52wk36 mga,b,c,d NCT06010004 · Phase 3 · registry result, not featured evidence show 2 more doses-1.9 kg @ 52wk12 mg NCT06010004 · Phase 3 · registry result, not featured evidence -0.7 kg @ 52wk3 mg NCT06010004 · Phase 3 · registry result, not featured evidence | -2.5 kg @ 40wk2.0 mg weeklya,b,c,d NCT03989232 · Phase 3 show 1 more dose-2.1 kg @ 40wk1.0 mg weekly NCT03989232 · Phase 3 |
| HbA1c absolute change · percentage points No placebo or comparator arm | -2.13% (n=125) @ 52wk36 mga,b,c NCT06010004 · Phase 3 · registry result, not featured evidence show 2 more doses-1.97% (n=128) @ 52wk12 mg NCT06010004 · Phase 3 · registry result, not featured evidence -1.71% (n=125) @ 52wk3 mg NCT06010004 · Phase 3 · registry result, not featured evidence | -1.23% (n=91) @ 52wkb,c NCT05813912 · Phase 3 · registry result, not featured evidence · combination 1 other source trial-0.86% (n=335) @ 52wk NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 |
| HbA1c Less Than 7% responder rate · % of participants No placebo or comparator arm | 90.82% (n=125) @ 52wk36 mga,b,c,d NCT06010004 · Phase 3 · registry result, not featured evidence show 2 more doses86.11% (n=128) @ 52wk12 mg NCT06010004 · Phase 3 · registry result, not featured evidence 82.73% (n=125) @ 52wk3 mg NCT06010004 · Phase 3 · registry result, not featured evidence | 67.6% (n=480) @ 40wk2.0 mg weeklya,b,c,d NCT03989232 · Phase 3 show 1 more dose57.5% (n=481) @ 40wk1.0 mg weekly NCT03989232 · Phase 3 |
| HbA1c Less Than or Equal to 6.5 responder rate · % of participants | 68.91% (n=119) vs 18.56% (n=97) placebo @ 40wk36 mga,e,b,c NCT05971940 · Phase 3 · registry result, not featured evidence show 2 more doses68.75% (n=112) vs 18.56% (n=97) placebo @ 40wk12 mg NCT05971940 · Phase 3 · registry result, not featured evidence 66.39% (n=119) vs 18.56% (n=97) placebo @ 40wk3 mg NCT05971940 · Phase 3 · registry result, not featured evidence | 66.7% (n=300) vs 34.1% (n=299) Dulaglutide @ 40wk1.0 mga,e,b,c NCT02648204 · Phase 3 · registry result, not featured evidence show 1 more dose49.2% (n=301) vs 34.1% (n=299) Dulaglutide @ 40wk0.5 mg NCT02648204 · Phase 3 · registry result, not featured evidence |
| HbA1c Less Than or Equal to 6.5 responder rate · % of participants No placebo or comparator arm | 84.56% (n=125) @ 52wk36 mga,b,c,d NCT06010004 · Phase 3 · registry result, not featured evidence show 2 more doses76.23% (n=128) @ 52wk12 mg NCT06010004 · Phase 3 · registry result, not featured evidence 62.64% (n=125) @ 52wk3 mg NCT06010004 · Phase 3 · registry result, not featured evidence | 51.7% (n=480) @ 40wk2.0 mg weeklya,b,c,d NCT03989232 · Phase 3 show 1 more dose38.5% (n=481) @ 40wk1.0 mg weekly NCT03989232 · Phase 3 |
| SBP absolute change · mmHg | -6 vs -0.5 placebo mmHg @ 40wk36 mga,f,c,g NCT05971940 · Phase 3 · registry result, not featured evidence show 2 more doses-6.1 vs -0.5 placebo mmHg @ 40wk12 mg NCT05971940 · Phase 3 · registry result, not featured evidence -3.2 vs -0.5 placebo mmHg @ 40wk3 mg NCT05971940 · Phase 3 · registry result, not featured evidence | -3.9 vs -1.4 placebo mmHg @ 104wkf,c,g NCT03819153 · Phase 3 1 other source trial-3 vs -2.8 Standard of Care mmHg @ 104wk NCT03596450 · Phase 4 · registry result, not featured evidence |
| Waist Circumference Change absolute change · cm No placebo or comparator arm | -6.5 cm @ 52wk36 mga,b,c,d NCT06010004 · Phase 3 · registry result, not featured evidence show 2 more doses-4.6 cm @ 52wk12 mg NCT06010004 · Phase 3 · registry result, not featured evidence -2.4 cm @ 52wk3 mg NCT06010004 · Phase 3 · registry result, not featured evidence | -5.9 cm @ 40wk2.0 mg weeklya,b,c,d NCT03989232 · Phase 3 show 1 more dose-5.2 cm @ 40wk1.0 mg weekly NCT03989232 · Phase 3 |
| Weight percent change · % of baseline | -9.6% vs -2.5% placebo @ 72wkorforglipron 17.2 mgb,c NCT05872620 · Phase 3 · sponsor-reported, not registry data | -13.5% (n=291) vs -4% (n=95) placebo @ 72wk7.2 mgb,c NCT05649137 · Phase 3 · registry result, not featured evidence |
| Weight absolute change · kg No placebo or comparator arm | -6.75 kg @ 52wk36 mga,b,c NCT06010004 · Phase 3 · registry result, not featured evidence show 2 more doses-5.08 kg @ 52wk12 mg NCT06010004 · Phase 3 · registry result, not featured evidence -1.81 kg @ 52wk3 mg NCT06010004 · Phase 3 · registry result, not featured evidence | -3.85 kg @ 52wkb,c NCT05813912 · Phase 3 · registry result, not featured evidence · combination 1 other source trial-3.77 kg @ 52wk NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 |
| Weight Loss 10% responder rate · % of participants No placebo or comparator arm | 37.91% (n=125) @ 52wk36 mga,b,c,d NCT06010004 · Phase 3 · registry result, not featured evidence show 2 more doses24.68% (n=127) @ 52wk12 mg NCT06010004 · Phase 3 · registry result, not featured evidence 10.11% (n=125) @ 52wk3 mg NCT06010004 · Phase 3 · registry result, not featured evidence | 28.4% (n=480) @ 40wk2.0 mg weeklya,b,c,d NCT03989232 · Phase 3 show 1 more dose22.6% (n=481) @ 40wk1.0 mg weekly NCT03989232 · Phase 3 |
| Weight Loss 5% responder rate · % of participants | 66.39% (n=119) vs 14.58% (n=96) placebo @ 40wk36 mga,e,b,c NCT05971940 · Phase 3 · registry result, not featured evidence show 2 more doses58.56% (n=111) vs 14.58% (n=96) placebo @ 40wk12 mg NCT05971940 · Phase 3 · registry result, not featured evidence 47.06% (n=119) vs 14.58% (n=96) placebo @ 40wk3 mg NCT05971940 · Phase 3 · registry result, not featured evidence | 63% (n=300) vs 22.7% (n=299) Dulaglutide @ 40wk1.0 mga,e,b,c NCT02648204 · Phase 3 · registry result, not featured evidence show 1 more dose43.9% (n=301) vs 22.7% (n=299) Dulaglutide @ 40wk0.5 mg NCT02648204 · Phase 3 · registry result, not featured evidence |
| Weight Loss 5% responder rate · % of participants No placebo or comparator arm | 65.14% (n=125) @ 52wk36 mga,b,c,d NCT06010004 · Phase 3 · registry result, not featured evidence show 2 more doses49.52% (n=127) @ 52wk12 mg NCT06010004 · Phase 3 · registry result, not featured evidence 27% (n=125) @ 52wk3 mg NCT06010004 · Phase 3 · registry result, not featured evidence | 59.2% (n=480) @ 40wk2.0 mg weeklya,b,c,d NCT03989232 · Phase 3 show 1 more dose51.3% (n=481) @ 40wk1.0 mg weekly NCT03989232 · Phase 3 |
| Dropout rate | 6.7%36 mgh NCT06010004 · Phase 3 · registry result, not featured evidence show 19 more results5.2%12 mg NCT06010004 · Phase 3 · registry result, not featured evidence 5.3%3 mg NCT06010004 · Phase 3 · registry result, not featured evidence 3.5%36 mg NCT05971940 · Phase 3 · registry result, not featured evidence 8.8%12 mg NCT05971940 · Phase 3 · registry result, not featured evidence 6.3%3 mg NCT05971940 · Phase 3 · registry result, not featured evidence 7.4%36 mg NCT05048719 · Phase 2 · registry result, not featured evidence 11.8%36 mg NCT05048719 · Phase 2 · registry result, not featured evidence 10.7%12 mg NCT05048719 · Phase 2 · registry result, not featured evidence 7.8%3 mg NCT05048719 · Phase 2 · registry result, not featured evidence 6.5%45 mg NCT05048719 · Phase 2 · registry result, not featured evidence 9.4%45 mg NCT05048719 · Phase 2 · registry result, not featured evidence 10.6%24 mg NCT05048719 · Phase 2 · registry result, not featured evidence —3 mg NCT05086445 · Phase 1 · registry result, not featured evidence —2 mg NCT05086445 · Phase 1 · registry result, not featured evidence 10%3/6/12/15 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 57.1%3/6/12/21 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 11.1%3/6/12/21/27 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 0%3/6/9 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 0%3/6/9/21/36/45 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence | 1.3%1.0 mgi NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 show 47 more results1.7%0.5 mg NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 —1.0 mg NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 7.9%1.0 mg NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 2.4% NCT03819153 · Phase 3 5.4%1.0 mg weekly NCT02054897 · Phase 3 7.8%0.5 mg weekly NCT02054897 · Phase 3 5.1%1.0 mg weekly NCT01930188 · Phase 3 · combination 5.4%0.5 mg weekly NCT01930188 · Phase 3 · combination 5.3%1.0 mg/week NCT02128932 · Phase 3 7.5%0.5 mg/week NCT02128932 · Phase 3 3.8%2.0 mg weekly NCT03989232 · Phase 3 2.1%1.0 mg weekly NCT03989232 · Phase 3 3.8%1.0 mg weekly NCT02305381 · Phase 3 3.8%0.5 mg weekly NCT02305381 · Phase 3 0% NCT04126603 · Phase 4 · registry result, not featured evidence 0% NCT05786521 · Phase 4 · registry result, not featured evidence 10.6% NCT05533632 · Phase 4 · registry result, not featured evidence 0%once weekly NCT04538352 · Phase 4 · registry result, not featured evidence · combination 28.1% NCT03596450 · Phase 4 · registry result, not featured evidence 36.5%Insulin Icodec + Semaglutide NCT05813912 · Phase 3 · registry result, not featured evidence · combination —Insulin Icodec + Semaglutide: Trea NCT05813912 · Phase 3 · registry result, not featured evidence · combination —INSULIN GLARGINE (REDUCED) + SEMAG NCT05514535 · Phase 3 · registry result, not featured evidence · combination 1.7%Insuline Glargine U100 (Reduced) + NCT05514535 · Phase 3 · registry result, not featured evidence · combination 3.9%7.2 mg NCT05649137 · Phase 3 · registry result, not featured evidence 18.3%1.0 mg NCT04865770 · Phase 3 · registry result, not featured evidence 7.6% NCT04560998 · Phase 3 · registry result, not featured evidence 1.5% NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 — NCT03689374 · Phase 3 · registry result, not featured evidence 9.7%1.0 mg weekly NCT03061214 · Phase 3 · registry result, not featured evidence 8.7%0.5 mg weekly NCT03061214 · Phase 3 · registry result, not featured evidence 6.9% NCT03136484 · Phase 3 · registry result, not featured evidence · combination 1%1.0 mg NCT03191396 · Phase 3 · registry result, not featured evidence 2.6%1.0 mg weekly NCT03086330 · Phase 3 · registry result, not featured evidence 7%1.0 mg NCT02648204 · Phase 3 · registry result, not featured evidence 7.3%0.5 mg NCT02648204 · Phase 3 · registry result, not featured evidence 4.1%1.0 mg NCT02207374 · Phase 3 · registry result, not featured evidence 2.5%0.5 mg NCT02207374 · Phase 3 · registry result, not featured evidence 2.9%1.0 mg NCT02254291 · Phase 3 · registry result, not featured evidence 0%0.5 mg NCT02254291 · Phase 3 · registry result, not featured evidence 8.2%2.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence 11.3%16.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence 12.9%8.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence 3.4%21.6 mg NCT05144984 · Phase 2 · registry result, not featured evidence 3.9%2.4 mg + 12.0 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 3.9%2.4 mg + 2.4 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 3.9%2.4 mg + 21.6 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 2.7%2.4 mg + 7.2 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 2.2%36 mgh NCT06010004 · Phase 3 · registry result, not featured evidence show 19 more results4.4%12 mg NCT06010004 · Phase 3 · registry result, not featured evidence 1.5%3 mg NCT06010004 · Phase 3 · registry result, not featured evidence 1.4%36 mg NCT05971940 · Phase 3 · registry result, not featured evidence 0%12 mg NCT05971940 · Phase 3 · registry result, not featured evidence 0.7%3 mg NCT05971940 · Phase 3 · registry result, not featured evidence 3.7%36 mg NCT05048719 · Phase 2 · registry result, not featured evidence 0%36 mg NCT05048719 · Phase 2 · registry result, not featured evidence 3.6%12 mg NCT05048719 · Phase 2 · registry result, not featured evidence 2%3 mg NCT05048719 · Phase 2 · registry result, not featured evidence 0%45 mg NCT05048719 · Phase 2 · registry result, not featured evidence 0%45 mg NCT05048719 · Phase 2 · registry result, not featured evidence 0%24 mg NCT05048719 · Phase 2 · registry result, not featured evidence —3 mg NCT05086445 · Phase 1 · registry result, not featured evidence —2 mg NCT05086445 · Phase 1 · registry result, not featured evidence 10%3/6/12/15 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 35.7%3/6/12/21 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 11.1%3/6/12/21/27 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 0%3/6/9 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 0%3/6/9/21/36/45 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence | —1.0 mgi NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 show 47 more results—0.5 mg NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 —1.0 mg NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —1.0 mg NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 — NCT03819153 · Phase 3 —1.0 mg weekly NCT02054897 · Phase 3 —0.5 mg weekly NCT02054897 · Phase 3 —1.0 mg weekly NCT01930188 · Phase 3 · combination —0.5 mg weekly NCT01930188 · Phase 3 · combination —1.0 mg/week NCT02128932 · Phase 3 —0.5 mg/week NCT02128932 · Phase 3 —2.0 mg weekly NCT03989232 · Phase 3 —1.0 mg weekly NCT03989232 · Phase 3 —1.0 mg weekly NCT02305381 · Phase 3 —0.5 mg weekly NCT02305381 · Phase 3 — NCT04126603 · Phase 4 · registry result, not featured evidence — NCT05786521 · Phase 4 · registry result, not featured evidence 3.8% NCT05533632 · Phase 4 · registry result, not featured evidence —once weekly NCT04538352 · Phase 4 · registry result, not featured evidence · combination 2.2% NCT03596450 · Phase 4 · registry result, not featured evidence —Insulin Icodec + Semaglutide NCT05813912 · Phase 3 · registry result, not featured evidence · combination —Insulin Icodec + Semaglutide: Trea NCT05813912 · Phase 3 · registry result, not featured evidence · combination —INSULIN GLARGINE (REDUCED) + SEMAG NCT05514535 · Phase 3 · registry result, not featured evidence · combination —Insuline Glargine U100 (Reduced) + NCT05514535 · Phase 3 · registry result, not featured evidence · combination —7.2 mg NCT05649137 · Phase 3 · registry result, not featured evidence —1.0 mg NCT04865770 · Phase 3 · registry result, not featured evidence — NCT04560998 · Phase 3 · registry result, not featured evidence — NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 — NCT03689374 · Phase 3 · registry result, not featured evidence —1.0 mg weekly NCT03061214 · Phase 3 · registry result, not featured evidence —0.5 mg weekly NCT03061214 · Phase 3 · registry result, not featured evidence — NCT03136484 · Phase 3 · registry result, not featured evidence · combination —1.0 mg NCT03191396 · Phase 3 · registry result, not featured evidence —1.0 mg weekly NCT03086330 · Phase 3 · registry result, not featured evidence 0%1.0 mg NCT02648204 · Phase 3 · registry result, not featured evidence 0%0.5 mg NCT02648204 · Phase 3 · registry result, not featured evidence —1.0 mg NCT02207374 · Phase 3 · registry result, not featured evidence —0.5 mg NCT02207374 · Phase 3 · registry result, not featured evidence —1.0 mg NCT02254291 · Phase 3 · registry result, not featured evidence —0.5 mg NCT02254291 · Phase 3 · registry result, not featured evidence —2.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence —16.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence —8.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence —21.6 mg NCT05144984 · Phase 2 · registry result, not featured evidence —2.4 mg + 12.0 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination —2.4 mg + 2.4 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination —2.4 mg + 21.6 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination —2.4 mg + 7.2 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | 4.5%36 mgh NCT06010004 · Phase 3 · registry result, not featured evidence show 19 more results2.2%12 mg NCT06010004 · Phase 3 · registry result, not featured evidence 3%3 mg NCT06010004 · Phase 3 · registry result, not featured evidence 2.8%36 mg NCT05971940 · Phase 3 · registry result, not featured evidence 5.1%12 mg NCT05971940 · Phase 3 · registry result, not featured evidence 5.6%3 mg NCT05971940 · Phase 3 · registry result, not featured evidence 3.7%36 mg NCT05048719 · Phase 2 · registry result, not featured evidence 2.9%36 mg NCT05048719 · Phase 2 · registry result, not featured evidence 1.8%12 mg NCT05048719 · Phase 2 · registry result, not featured evidence 5.9%3 mg NCT05048719 · Phase 2 · registry result, not featured evidence 0%45 mg NCT05048719 · Phase 2 · registry result, not featured evidence 3.1%45 mg NCT05048719 · Phase 2 · registry result, not featured evidence 10.6%24 mg NCT05048719 · Phase 2 · registry result, not featured evidence 0%3 mg NCT05086445 · Phase 1 · registry result, not featured evidence 0%2 mg NCT05086445 · Phase 1 · registry result, not featured evidence 0%3/6/12/15 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 0%3/6/12/21 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 0%3/6/12/21/27 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 0%3/6/9 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence 0%3/6/9/21/36/45 mg QD NCT04426474 · Phase 1 · registry result, not featured evidence | 33.6%1.0 mgi NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 show 47 more results35%0.5 mg NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 9.4%1.0 mg NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —1.0 mg NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 49.6% NCT03819153 · Phase 3 5.4%1.0 mg weekly NCT02054897 · Phase 3 5.5%0.5 mg weekly NCT02054897 · Phase 3 7.3%1.0 mg weekly NCT01930188 · Phase 3 · combination 7.3%0.5 mg weekly NCT01930188 · Phase 3 · combination 4.7%1.0 mg/week NCT02128932 · Phase 3 6.1%0.5 mg/week NCT02128932 · Phase 3 4.4%2.0 mg weekly NCT03989232 · Phase 3 5.2%1.0 mg weekly NCT03989232 · Phase 3 9.2%1.0 mg weekly NCT02305381 · Phase 3 6.1%0.5 mg weekly NCT02305381 · Phase 3 0% NCT04126603 · Phase 4 · registry result, not featured evidence 0% NCT05786521 · Phase 4 · registry result, not featured evidence 1% NCT05533632 · Phase 4 · registry result, not featured evidence 22.5%once weekly NCT04538352 · Phase 4 · registry result, not featured evidence · combination 6% NCT03596450 · Phase 4 · registry result, not featured evidence —Insulin Icodec + Semaglutide NCT05813912 · Phase 3 · registry result, not featured evidence · combination 3.2%Insulin Icodec + Semaglutide: Trea NCT05813912 · Phase 3 · registry result, not featured evidence · combination 5.9%INSULIN GLARGINE (REDUCED) + SEMAG NCT05514535 · Phase 3 · registry result, not featured evidence · combination —Insuline Glargine U100 (Reduced) + NCT05514535 · Phase 3 · registry result, not featured evidence · combination 9.8%7.2 mg NCT05649137 · Phase 3 · registry result, not featured evidence 19.7%1.0 mg NCT04865770 · Phase 3 · registry result, not featured evidence 18.7% NCT04560998 · Phase 3 · registry result, not featured evidence 6.2% NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 7.4% NCT03689374 · Phase 3 · registry result, not featured evidence 6.6%1.0 mg weekly NCT03061214 · Phase 3 · registry result, not featured evidence 6.3%0.5 mg weekly NCT03061214 · Phase 3 · registry result, not featured evidence 4.6% NCT03136484 · Phase 3 · registry result, not featured evidence · combination 5.9%1.0 mg NCT03191396 · Phase 3 · registry result, not featured evidence 4.7%1.0 mg weekly NCT03086330 · Phase 3 · registry result, not featured evidence 7.7%1.0 mg NCT02648204 · Phase 3 · registry result, not featured evidence 5.6%0.5 mg NCT02648204 · Phase 3 · registry result, not featured evidence 5%1.0 mg NCT02207374 · Phase 3 · registry result, not featured evidence 7.9%0.5 mg NCT02207374 · Phase 3 · registry result, not featured evidence 2%1.0 mg NCT02254291 · Phase 3 · registry result, not featured evidence 5.8%0.5 mg NCT02254291 · Phase 3 · registry result, not featured evidence 6.7%2.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence 1.6%16.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence 3.3%8.0 mg NCT05486065 · Phase 2 · registry result, not featured evidence 3.4%21.6 mg NCT05144984 · Phase 2 · registry result, not featured evidence 2.6%2.4 mg + 12.0 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 7.8%2.4 mg + 2.4 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 6.5%2.4 mg + 21.6 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination 4.1%2.4 mg + 7.2 mg NCT05144984 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | 36 mgh constipation 29.1% nausea 27.6% nasopharyngitis 16.4% NCT06010004 · Phase 3 · registry result, not featured evidence show 19 more results12 mg constipation 30.4% nasopharyngitis 22.2% nausea 19.3% NCT06010004 · Phase 3 · registry result, not featured evidence 3 mg nasopharyngitis 17.4% constipation 16.7% nausea 12.9% NCT06010004 · Phase 3 · registry result, not featured evidence 36 mg diarrhoea 25.5% (placebo 9.4%) diabetic retinopathy 17% (placebo 15.2%) nausea 17% (placebo 2.2%) NCT05971940 · Phase 3 · registry result, not featured evidence 12 mg diarrhoea 21.2% (placebo 9.4%) dyspepsia 21.2% (placebo 7.2%) nausea 19% (placebo 2.2%) NCT05971940 · Phase 3 · registry result, not featured evidence 3 mg diarrhoea 18.9% (placebo 9.4%) diabetic retinopathy 14.7% (placebo 15.2%) nausea 12.6% (placebo 2.2%) NCT05971940 · Phase 3 · registry result, not featured evidence 36 mg nausea 37% (placebo 5.5%) vomiting 33.3% (placebo 1.8%) diarrhoea 25.9% (placebo 7.3%) NCT05048719 · Phase 2 · registry result, not featured evidence 36 mg nausea 26.5% (placebo 5.5%) vomiting 20.6% (placebo 1.8%) eructation 8.8% (placebo 0%) NCT05048719 · Phase 2 · registry result, not featured evidence 12 mg nausea 37.5% (placebo 5.5%) vomiting 21.4% (placebo 1.8%) diarrhoea 16.1% (placebo 7.3%) NCT05048719 · Phase 2 · registry result, not featured evidence 3 mg nausea 23.5% (placebo 5.5%) diarrhoea 21.6% (placebo 7.3%) constipation 13.7% (placebo 1.8%) NCT05048719 · Phase 2 · registry result, not featured evidence 45 mg vomiting 35.5% (placebo 1.8%) diarrhoea 29% (placebo 7.3%) nausea 29% (placebo 5.5%) NCT05048719 · Phase 2 · registry result, not featured evidence 45 mg diarrhoea 28.1% (placebo 7.3%) nausea 25% (placebo 5.5%) vomiting 21.9% (placebo 1.8%) NCT05048719 · Phase 2 · registry result, not featured evidence 24 mg nausea 34% (placebo 5.5%) vomiting 27.7% (placebo 1.8%) diarrhoea 14.9% (placebo 7.3%) NCT05048719 · Phase 2 · registry result, not featured evidence 3 mg nausea 55.6% (placebo 25%) constipation 33.3% (placebo 0%) vomiting 22.2% (placebo 25%) NCT05086445 · Phase 1 · registry result, not featured evidence 2 mg vomiting 40% (placebo 25%) nausea 30% (placebo 25%) abdominal distension 20% (placebo 0%) NCT05086445 · Phase 1 · registry result, not featured evidence 3/6/12/15 mg QD nausea 50% (placebo 5.9%) vomiting 50% (placebo 0%) decreased appetite 40% (placebo 11.8%) NCT04426474 · Phase 1 · registry result, not featured evidence 3/6/12/21 mg QD nausea 42.9% (placebo 5.9%) decreased appetite 28.6% (placebo 11.8%) covid-19 21.4% (placebo 5.9%) NCT04426474 · Phase 1 · registry result, not featured evidence 3/6/12/21/27 mg QD decreased appetite 55.6% (placebo 11.8%) vomiting 55.6% (placebo 0%) nausea 33.3% (placebo 5.9%) NCT04426474 · Phase 1 · registry result, not featured evidence 3/6/9 mg QD vomiting 55.6% (placebo 0%) decreased appetite 44.4% (placebo 11.8%) nausea 44.4% (placebo 5.9%) NCT04426474 · Phase 1 · registry result, not featured evidence 3/6/9/21/36/45 mg QD nausea 77.8% (placebo 5.9%) decreased appetite 66.7% (placebo 11.8%) vomiting 55.6% (placebo 0%) NCT04426474 · Phase 1 · registry result, not featured evidence | 1.0 mgi nausea 21.8% (placebo 7.5%) diarrhoea 18% (placebo 11.8%) vomiting 14.8% (placebo 5.1%) NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 show 42 more results0.5 mg diarrhoea 17.9% (placebo 11.8%) nausea 17.3% (placebo 7.5%) lipase increased 11.4% (placebo 8%) NCT01720446 · Phase 3 · add on · Type 2 Diabetes · phase 3 1.0 mg nausea 22.3% diarrhoea 11.4% lipase increased 10.1% NCT01885208 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 1.0 mg weekly nausea 23.8% (placebo 7.8%) diarrhoea 10.8% (placebo 2.3%) headache 6.9% (placebo 6.2%) NCT02054897 · Phase 3 0.5 mg weekly nausea 20.3% (placebo 7.8%) diarrhoea 12.5% (placebo 2.3%) headache 11.7% (placebo 6.2%) NCT02054897 · Phase 3 1.0 mg weekly nausea 16.8% (placebo 4.5%) vomiting 11.5% (placebo 3%) diarrhoea 6.9% (placebo 1.5%) NCT02305381 · Phase 3 0.5 mg weekly nausea 11.4% (placebo 4.5%) lipase increased 9.1% (placebo 3%) nasopharyngitis 8.3% (placebo 10.5%) NCT02305381 · Phase 3 abdominal pain 60% NCT05786521 · Phase 4 · registry result, not featured evidence once weekly pain 17.5% upper respiratory infection 0% NCT04538352 · Phase 4 · registry result, not featured evidence · combination nausea 19.1% vomiting 8.5% upper respiratory tract infection 7.4% NCT05813912 · Phase 3 · registry result, not featured evidence · combination nausea 18.4% diarrhoea 13.5% vomiting 9.7% NCT05514535 · Phase 3 · registry result, not featured evidence · combination 7.2 mg nausea 29% (placebo 11.8%) diarrhoea 18.2% (placebo 8.8%) vomiting 16.6% (placebo 2.9%) NCT05649137 · Phase 3 · registry result, not featured evidence 1.0 mg covid-19 5.6% (placebo 0%) decreased appetite 5.6% (placebo 0%) diabetic retinopathy 5.6% (placebo 5.7%) NCT04865770 · Phase 3 · registry result, not featured evidence covid-19 7.6% (placebo 5.3%) nausea 5.6% (placebo 0.8%) NCT04560998 · Phase 3 · registry result, not featured evidence covid-19 14.4% diarrhoea 12.1% nausea 11.5% NCT05259033 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3 nausea 14.8% diarrhoea 7.4% nasopharyngitis 6.5% NCT03689374 · Phase 3 · registry result, not featured evidence 1.0 mg weekly diarrhoea 16.9% nausea 13.4% upper respiratory tract infection 13.1% NCT03061214 · Phase 3 · registry result, not featured evidence 0.5 mg weekly diarrhoea 20.2% upper respiratory tract infection 9.8% lipase increased 7.7% NCT03061214 · Phase 3 · registry result, not featured evidence nausea 22.7% diarrhoea 15.1% vomiting 12.8% NCT03136484 · Phase 3 · registry result, not featured evidence · combination 1.0 mg nausea 21.5% diarrhoea 15.6% decreased appetite 10.4% NCT03191396 · Phase 3 · registry result, not featured evidence 1.0 mg weekly nausea 19.3% (placebo 3.3%) diarrhoea 11.3% (placebo 6%) vomiting 9.3% (placebo 2%) NCT03086330 · Phase 3 · registry result, not featured evidence 1.0 mg nausea 21% diarrhoea 13.7% vomiting 10.3% NCT02648204 · Phase 3 · registry result, not featured evidence 0.5 mg nausea 22.3% diarrhoea 14.3% vomiting 10% NCT02648204 · Phase 3 · registry result, not featured evidence 1.0 mg nasopharyngitis 31.1% nausea 19.1% diarrhoea 15.8% NCT02207374 · Phase 3 · registry result, not featured evidence 0.5 mg nasopharyngitis 33.9% constipation 18.4% nausea 12.1% NCT02207374 · Phase 3 · registry result, not featured evidence 1.0 mg nasopharyngitis 17.6% nausea 12.7% constipation 11.8% NCT02254291 · Phase 3 · registry result, not featured evidence 0.5 mg nasopharyngitis 16.5% constipation 14.6% nausea 10.7% NCT02254291 · Phase 3 · registry result, not featured evidence 2.0 mg nausea 21.7% (placebo 15.3%) vomiting 18.3% (placebo 6.8%) diarrhoea 15% (placebo 11.9%) NCT05486065 · Phase 2 · registry result, not featured evidence 16.0 mg nausea 37.1% (placebo 15.3%) vomiting 25.8% (placebo 6.8%) diarrhoea 21% (placebo 11.9%) NCT05486065 · Phase 2 · registry result, not featured evidence 8.0 mg nausea 41.7% (placebo 15.3%) diarrhoea 33.3% (placebo 11.9%) vomiting 23.3% (placebo 6.8%) NCT05486065 · Phase 2 · registry result, not featured evidence 21.6 mg injection site erythema 10.2% (placebo 0%) injection site reaction 10.2% (placebo 0%) diarrhoea 8.5% (placebo 11.5%) NCT05144984 · Phase 2 · registry result, not featured evidence 2.4 mg + 12.0 mg diarrhoea 14.3% (placebo 11.5%) constipation 9.1% (placebo 1.6%) covid-19 7.8% (placebo 13.1%) NCT05144984 · Phase 2 · registry result, not featured evidence · combination 2.4 mg + 2.4 mg nausea 19.5% (placebo 1.6%) diarrhoea 14.3% (placebo 11.5%) covid-19 7.8% (placebo 13.1%) NCT05144984 · Phase 2 · registry result, not featured evidence · combination 2.4 mg + 21.6 mg diarrhoea 13% (placebo 11.5%) nausea 13% (placebo 1.6%) covid-19 11.7% (placebo 13.1%) NCT05144984 · Phase 2 · registry result, not featured evidence · combination 2.4 mg + 7.2 mg diarrhoea 21.6% (placebo 11.5%) lipase increased 12.2% (placebo 3.3%) nausea 12.2% (placebo 1.6%) NCT05144984 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 40 weeks versus 52 weeks.
- eThe reported result categories differ.
- fPopulation context differs: registered conditions differ.
- gAssessment timepoints differ: 104 weeks versus 40 weeks.
- hPopulation comparability has not been reviewed for these studies.
- iPopulation comparability has not been reviewed for 43 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
orforglipron
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 7 more results
show 2 more results
show 2 more results
show 2 more results
show 4 more results
show 4 more results
Semaglutide (Ozempic)
show 1 more result
show 7 more results
show 1 more result
show 4 more results
+ 103 further endpoints in the CSV export.
Atherosclerotic Cardiovascular Disease
Shared mechanism: GLP-1 receptor · full Atherosclerotic Cardiovascular Disease pipeline
orforglipron · Foundayo
Marketed by Eli Lilly and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2028 · NCT07223593 (registry estimate)
No aligned efficacy figure on record for this race.
Semaglutide (Ozempic)
Marketed by Novo Nordisk
NCT01720446 · Phase 3 · completed
This was a large randomized, double-blind, placebo-controlled trial with 1,648 participants receiving semaglutide and 1,649 receiving placebo. The hard clinical primary endpoint, first major adverse cardiovascular event, occurred in 6.6% versus 8.9% of participants; the prespecified non-inferiority comparison was met (hazard ratio 0.74, 95% CI 0.58–0.95, p<0.0001), and a post hoc superiority analysis was statistically significant (p=0.0167).
Next expected readout: July 2028 · NCT07073053 (registry estimate)
Reported efficacy
Change in Maximum Walking Distance on a Constant Load Treadmill Test (Baseline (week 0), end of treatment (week 52)): Maximum walking distance at Week 52: semaglutide 1 mg superior to placebo by 13% (estimated treatment ratio 1.13; 95% CI 1.06-1.21; p=0.0004); median treatment difference 26.4 meters (~87 feet) on a 12% incline treadmill (met)
Result source: NCT04560998
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | orforglipron | Semaglutide (Ozempic) |
|---|---|---|
| LDL-C, % change | —Trial running · NCT07223593 | —Not reported |
| Non-HDL-C, % change | —Trial running · NCT07223593 | —Not reported |
| ApoB, % change | —Trial running · NCT07223593 | —Not reported |
| Lp(a), % change | —Trial running · NCT07223593 | —Not reported |
| 3-point MACE (% with event) | —Trial running · NCT07223593 | —Not reported |
LDL-C, % change
- orforglipron
- —Trial running · NCT07223593
- Semaglutide (Ozempic)
- —Not reported
Non-HDL-C, % change
- orforglipron
- —Trial running · NCT07223593
- Semaglutide (Ozempic)
- —Not reported
ApoB, % change
- orforglipron
- —Trial running · NCT07223593
- Semaglutide (Ozempic)
- —Not reported
Lp(a), % change
- orforglipron
- —Trial running · NCT07223593
- Semaglutide (Ozempic)
- —Not reported
3-point MACE (% with event)
- orforglipron
- —Trial running · NCT07223593
- Semaglutide (Ozempic)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
orforglipron: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. orforglipron: 0 of 4 rows · Semaglutide (Ozempic): 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Semaglutide (Ozempic) |
|---|---|
| Dropout rate | 7.6%a NCT04560998 · Phase 3 |
| Discontinued due to AEs | —a NCT04560998 · Phase 3 |
| Serious AEs | 18.7%a NCT04560998 · Phase 3 |
| Most frequent reported AEs |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Semaglutide (Ozempic)
show 1 more result
show 1 more result
+ 2 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: orforglipron's landscape · Semaglutide (Ozempic)'s landscape